Annual Gross Profit
$636.89 M
+$116.08 M+22.29%
31 December 2023
Summary:
Halozyme Therapeutics annual gross profit is currently $636.89 million, with the most recent change of +$116.08 million (+22.29%) on 31 December 2023. During the last 3 years, it has risen by +$275.00 million (+75.99%). HALO annual gross profit is now at all-time high.HALO Gross Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Gross Profit
$240.66 M
+$48.91 M+25.51%
30 September 2024
Summary:
Halozyme Therapeutics quarterly gross profit is currently $240.66 million, with the most recent change of +$48.91 million (+25.51%) on 30 September 2024. Over the past year, it has increased by +$62.92 million (+35.40%). HALO quarterly gross profit is now at all-time high.HALO Quarterly Gross Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Gross Profit
$777.70 M
+$79.45 M+11.38%
30 September 2024
Summary:
Halozyme Therapeutics TTM gross profit is currently $777.70 million, with the most recent change of +$79.45 million (+11.38%) on 30 September 2024. Over the past year, it has increased by +$140.80 million (+22.11%). HALO TTM gross profit is now at all-time high.HALO TTM Gross Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Gross Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +35.4% | +22.1% |
| 3 y3 years | +76.0% | +199.3% | +114.9% |
| 5 y5 years | +323.3% | +550.8% | +416.9% |
HALO Gross Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +76.0% | at high | +199.3% | at high | +114.9% |
| 5 y | 5 years | at high | +323.3% | at high | +1129.9% | at high | +560.7% |
| alltime | all time | at high | at high | >+9999.0% | at high | >+9999.0% |
Halozyme Therapeutics Gross Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $240.66 M(+25.5%) | $777.70 M(+11.4%) |
| June 2024 | - | $191.75 M(+14.4%) | $698.25 M(+3.1%) |
| Mar 2024 | - | $167.55 M(-5.7%) | $677.47 M(+6.4%) |
| Dec 2023 | $636.89 M(+22.3%) | $177.74 M(+10.3%) | $636.89 M(+6.4%) |
| Sept 2023 | - | $161.21 M(-5.7%) | $598.53 M(-0.1%) |
| June 2023 | - | $170.97 M(+34.6%) | $598.97 M(+9.6%) |
| Mar 2023 | - | $126.97 M(-8.9%) | $546.43 M(+4.9%) |
| Dec 2022 | $520.81 M(+43.9%) | $139.38 M(-13.8%) | $520.81 M(+12.8%) |
| Sept 2022 | - | $161.66 M(+36.5%) | $461.85 M(+16.2%) |
| June 2022 | - | $118.42 M(+16.8%) | $397.44 M(+1.3%) |
| Mar 2022 | - | $101.36 M(+26.0%) | $392.45 M(+8.4%) |
| Dec 2021 | $361.90 M(+61.4%) | $80.42 M(-17.3%) | $361.90 M(-4.0%) |
| Sept 2021 | - | $97.24 M(-14.3%) | $376.91 M(+11.0%) |
| June 2021 | - | $113.44 M(+60.2%) | $339.42 M(+23.2%) |
| Mar 2021 | - | $70.80 M(-25.8%) | $275.46 M(+22.9%) |
| Dec 2020 | $224.23 M(+49.0%) | $95.43 M(+59.7%) | $224.23 M(+35.3%) |
| Sept 2020 | - | $59.75 M(+20.7%) | $165.77 M(+27.6%) |
| June 2020 | - | $49.48 M(+152.9%) | $129.92 M(+10.4%) |
| Mar 2020 | - | $19.57 M(-47.1%) | $117.71 M(-21.8%) |
| Dec 2019 | $150.45 M(+6.2%) | $36.98 M(+54.7%) | $150.45 M(-10.5%) |
| Sept 2019 | - | $23.90 M(-35.9%) | $168.08 M(-0.6%) |
| June 2019 | - | $37.27 M(-28.7%) | $169.11 M(+1.7%) |
| Mar 2019 | - | $52.30 M(-4.2%) | $166.21 M(+17.3%) |
| Dec 2018 | $141.73 M(-50.4%) | $54.61 M(+119.1%) | $141.73 M(-47.4%) |
| Sept 2018 | - | $24.93 M(-27.5%) | $269.19 M(-10.2%) |
| June 2018 | - | $34.37 M(+23.5%) | $299.66 M(+2.9%) |
| Mar 2018 | - | $27.82 M(-84.7%) | $291.26 M(+2.0%) |
| Dec 2017 | $285.46 M(+151.5%) | $182.08 M(+228.7%) | $285.46 M(+112.4%) |
| Sept 2017 | - | $55.40 M(+113.4%) | $134.39 M(+32.1%) |
| June 2017 | - | $25.96 M(+17.9%) | $101.71 M(+0.9%) |
| Mar 2017 | - | $22.02 M(-29.0%) | $100.77 M(-11.2%) |
| Dec 2016 | $113.48 M(+7.3%) | $31.00 M(+36.5%) | $113.48 M(-10.1%) |
| Sept 2016 | - | $22.72 M(-9.2%) | $126.28 M(+6.9%) |
| June 2016 | - | $25.03 M(-28.0%) | $118.17 M(-8.0%) |
| Mar 2016 | - | $34.74 M(-20.7%) | $128.38 M(+21.3%) |
| Dec 2015 | $105.81 M(+101.2%) | $43.80 M(+200.0%) | $105.81 M(+22.7%) |
| Sept 2015 | - | $14.60 M(-58.6%) | $86.24 M(+6.3%) |
| June 2015 | - | $35.24 M(+189.5%) | $81.11 M(+39.1%) |
| Mar 2015 | - | $12.17 M(-49.8%) | $58.33 M(+10.9%) |
| Dec 2014 | $52.60 M | $24.23 M(+156.0%) | $52.60 M(+40.9%) |
| Sept 2014 | - | $9.46 M(-24.0%) | $37.33 M(-13.6%) |
| June 2014 | - | $12.46 M(+93.3%) | $43.20 M(-1.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $6.45 M(-28.0%) | $43.90 M(-9.6%) |
| Dec 2013 | $48.55 M(+17.8%) | $8.96 M(-41.6%) | $48.55 M(-20.1%) |
| Sept 2013 | - | $15.33 M(+16.4%) | $60.73 M(+20.2%) |
| June 2013 | - | $13.17 M(+18.7%) | $50.51 M(+12.4%) |
| Mar 2013 | - | $11.10 M(-47.5%) | $44.96 M(+9.0%) |
| Dec 2012 | $41.23 M(-26.1%) | $21.14 M(+313.9%) | $41.23 M(+83.7%) |
| Sept 2012 | - | $5.11 M(-32.9%) | $22.45 M(-44.3%) |
| June 2012 | - | $7.61 M(+3.3%) | $40.27 M(-27.7%) |
| Mar 2012 | - | $7.37 M(+212.9%) | $55.67 M(-0.3%) |
| Dec 2011 | $55.83 M(+341.7%) | $2.35 M(-89.7%) | $55.83 M(-0.6%) |
| Sept 2011 | - | $22.93 M(-0.3%) | $56.16 M(+53.4%) |
| June 2011 | - | $23.01 M(+205.5%) | $36.62 M(+118.8%) |
| Mar 2011 | - | $7.53 M(+180.7%) | $16.73 M(+32.4%) |
| Dec 2010 | $12.64 M(-5.4%) | $2.68 M(-20.8%) | $12.64 M(-22.2%) |
| Sept 2010 | - | $3.39 M(+8.3%) | $16.24 M(+2.9%) |
| June 2010 | - | $3.13 M(-8.9%) | $15.78 M(+12.5%) |
| Mar 2010 | - | $3.44 M(-45.3%) | $14.03 M(+5.0%) |
| Dec 2009 | $13.36 M(+58.4%) | $6.28 M(+114.7%) | $13.36 M(+33.5%) |
| Sept 2009 | - | $2.93 M(+111.9%) | $10.01 M(+6.3%) |
| June 2009 | - | $1.38 M(-50.1%) | $9.42 M(-0.2%) |
| Mar 2009 | - | $2.77 M(-5.7%) | $9.43 M(+11.9%) |
| Dec 2008 | $8.43 M(+136.9%) | $2.93 M(+25.9%) | $8.43 M(+23.9%) |
| Sept 2008 | - | $2.33 M(+66.9%) | $6.81 M(+27.0%) |
| June 2008 | - | $1.40 M(-21.0%) | $5.36 M(+16.6%) |
| Mar 2008 | - | $1.77 M(+35.1%) | $4.59 M(+29.1%) |
| Dec 2007 | $3.56 M(+553.3%) | $1.31 M(+48.1%) | $3.56 M(+35.1%) |
| Sept 2007 | - | $883.40 K(+39.6%) | $2.64 M(+49.9%) |
| June 2007 | - | $633.00 K(-13.8%) | $1.76 M(+43.1%) |
| Mar 2007 | - | $734.00 K(+90.7%) | $1.23 M(+125.5%) |
| Dec 2006 | $544.80 K(+624.5%) | $384.90 K(+5914.1%) | $544.70 K(+179.6%) |
| Sept 2006 | - | $6400.00(-93.8%) | $194.80 K(-4.5%) |
| June 2006 | - | $103.10 K(+105.0%) | $204.00 K(+62.4%) |
| Mar 2006 | - | $50.30 K(+43.7%) | $125.60 K(+66.8%) |
| Dec 2005 | $75.20 K(>+9900.0%) | $35.00 K(+124.4%) | $75.30 K(+86.8%) |
| Sept 2005 | - | $15.60 K(-36.8%) | $40.30 K(+63.2%) |
| June 2005 | - | $24.70 K(>+9900.0%) | $24.70 K(-193.6%) |
| Dec 2003 | $0.00(0.0%) | - | - |
| June 2003 | - | $0.00(-100.0%) | -$26.40 K(<-9900.0%) |
| Dec 2002 | $0.00(-100.0%) | -$39.50 K(-401.5%) | $100.00(-99.7%) |
| Sept 2002 | - | $13.10 K(+3175.0%) | $39.60 K(+49.4%) |
| June 2002 | - | $400.00(-98.5%) | $26.50 K(+1.5%) |
| Mar 2002 | - | $26.10 K | $26.10 K |
| Dec 2001 | $8800.00 | - | - |
FAQ
- What is Halozyme Therapeutics annual gross profit?
- What is the all time high annual gross profit for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly gross profit?
- What is the all time high quarterly gross profit for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly gross profit year-on-year change?
- What is Halozyme Therapeutics TTM gross profit?
- What is the all time high TTM gross profit for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM gross profit year-on-year change?
What is Halozyme Therapeutics annual gross profit?
The current annual gross profit of HALO is $636.89 M
What is the all time high annual gross profit for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual gross profit is $636.89 M
What is Halozyme Therapeutics quarterly gross profit?
The current quarterly gross profit of HALO is $240.66 M
What is the all time high quarterly gross profit for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly gross profit is $240.66 M
What is Halozyme Therapeutics quarterly gross profit year-on-year change?
Over the past year, HALO quarterly gross profit has changed by +$62.92 M (+35.40%)
What is Halozyme Therapeutics TTM gross profit?
The current TTM gross profit of HALO is $777.70 M
What is the all time high TTM gross profit for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM gross profit is $777.70 M
What is Halozyme Therapeutics TTM gross profit year-on-year change?
Over the past year, HALO TTM gross profit has changed by +$140.80 M (+22.11%)